Greenwich LifeSciences
GLSI
23 hedge funds and large institutions have $6.06M invested in Greenwich LifeSciences in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 6 closing their positions.
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
1.55% less ownership
Funds ownership: 6.44% → 4.89% (-1.5%)
18% less funds holding
Funds holding: 28 → 23 (-5)
47% less capital invested
Capital invested by funds: $11.4M → $6.06M (-$5.35M)
83% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$318K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$232K |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$28.9K |
| 4 |
BlackRock
New York
|
+$9.2K |
| 5 |
NFSG
Newbridge Financial Services Group
Boca Raton,
Florida
|
+$6.71K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$784K |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$593K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$512K |
| 4 |
Millennium Management
New York
|
-$385K |
| 5 |
Jane Street
New York
|
-$255K |
GLSI Hedge Fund Activity: Q2 2023 in Review
23 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Greenwich LifeSciences (GLSI) for Q2 2023, worth a combined $6.06M — down 47% from $11.4M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of GLSI and 1 opened new positions — a net loss of 5 holders — while 7 trimmed existing stakes and 8 added.
The largest buyer was Renaissance Technologies, adding an estimated $318K. The largest seller was Vanguard Group, cutting an estimated $784K.
- 23 institutional investors held Greenwich LifeSciences (GLSI) as of Q2 2023, down from 28 in Q1 2023.
- Funds reported $6.06M of Greenwich LifeSciences stock for Q2 2023, down 47% quarter-over-quarter.
- 1 fund opened new Greenwich LifeSciences positions in Q2 2023 and 6 closed out, a net change of -5 holders.
- The largest Greenwich LifeSciences buyer in Q2 2023 was Renaissance Technologies, an estimated $318K added.
- The largest Greenwich LifeSciences seller in Q2 2023 was Vanguard Group, an estimated $784K sold.
Based on aggregated 13F filings for Q2 2023.